Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

mCRPC 1Prostatic Neoplasms 1

Interventions

Carboplatin 18Cisplatin 14pembrolizumab 13durvalumab 11Pemetrexed 11Paclitaxel 11Nivolumab 11Gemcitabine 11Rituximab 9trastuzumab deruxtecan 7osimertinib 6olaparib 6Dexamethasone 6Capecitabine 6atezolizumab 5acalabrutinib 5Specimen Handling 5Lenalidomide 5Bevacizumab 5130-nm albumin-bound paclitaxel 5tremelimumab 4niraparib 4cabozantinib 4amivantamab 4Prednisone 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × enzalutamide × Clear all
NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡